The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Read More
Ketogenic Diet and β-Hydroxybutyrate May Enhance CAR T-Cell Therapy Efficacy
December 7th 2024A ketogenic diet and its key metabolite, β-hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.
Read More
GLP1 Agonists and Dietary Fiber May Reduce VTE Risk and Improve GVHD Outcomes
December 7th 2024Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.
Read More
Experts Voice Concerns, Cautious Optimism With Kennedy Potentially Leading the HHS
December 6th 2024As experts in medication management and health education, pharmacists can work with the administration to promote effective strategies that reduce misinformation and improve public health outcomes.
Read More